ArticleIrish journal of medical science2025
Prevalence study of antimicrobial resistant organisms in very preterm neonates.
Article in Irish journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Evolution of Antimicrobial Resistance in Neonatal Sepsis: A Narrative Review.Antibiotics (Basel, Switzerland) · 2026Review
- Neonatal Infections Caused by Multidrug-Resistant Bacteria: An Analysis of Prevalence, Risk Factors, and Therapeutic Implications-A Narrative Review.Pathogens (Basel, Switzerland) · 2026Review
- A Review of Probiotic Interventions for Necrotizing Enterocolitis and Sepsis in Preterm Infants.International journal of molecular sciences · 2026Review
- Safeguarding future generations: a One Health perspective on children, climate change, and infectious threats.Frontiers in public health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreterm neonates have underdeveloped organs, a fragile skin barrier and an immature immune system rendering them susceptible to infection. These infants are at an increased risk of developing a healthcare-associated infection because of antibiotic exposure, invasive monitoring and the general risk of outbreaks within a hospital setting. The aim of this study was to investigate the prevalence of antimicrobial resistant organism carriage in very preterm neonates (i.e. born ≤ 32 weeks gestation) in the neonatal intensive care unit (NICU).
methodsNeonates born ≤ 32 weeks' gestation in NMH from September 2022 to January 2023 were included. Swabs were taken at admission and fortnightly until week 10 of life. Screening investigations included ESBL (Extended Spectrum Beta-Lactamases) and AmpC producers, organisms resistant to gentamicin and ciprofloxacin, CPE (Carbapenemase-producing Enterobacterales), MRSA (Methicillin-resistant Staphylococcus aureus) and VRE (Vancomycin-resistant Enterococci). This differed from baseline screening by frequency of screening, and the recording of presence of AmpC-producers and ciprofloxacin-resistance. Ethical approval was sought and granted.
resultsOverall, 20 out of the 53 neonates (38%) included in the study were colonised with one or more resistant-gram-negative organism; 5 with ESBL (9%), 2 resistant to gentamicin (4%), 6 resistant to ciprofloxacin (11%) and 14 (26%) with AmpC producers. Three (6%) resistant gram-negative bacilli were detected on admission screens, and resistance rates peaked at week 4 where 14 screens were positive. No CPE, MRSA or VRE were isolated. DISCUSSION/
conclusionThis study highlights the prevalence of antibiotic-resistant organisms in a vulnerable patient cohort, the very preterm infants. This review should prompt revision of the importance of infection prevention and control, antimicrobial stewardship and regular MDRO (multi-drug resistant organism) screening in the neonatal critical care setting.
Indexed as
Identifiers
40009276What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.